Abstract
Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Current Cancer Therapy Reviews
Title: Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Volume: 2 Issue: 2
Author(s): Gautam Sethi and Bharat B. Aggarwal
Affiliation:
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Abstract: Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Export Options
About this article
Cite this article as:
Sethi Gautam and Aggarwal B. Bharat, Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872834
DOI https://dx.doi.org/10.2174/157339406776872834 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy
Current Medicinal Chemistry The Therapeutic Potential of Targeting Autophagy in the Treatment of Cancer
Current Cancer Drug Targets Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Growth Factor/Peptide Receptor Imaging for the Development of Targeted Therapy in Oncology
Current Pharmaceutical Design Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development
Current Pharmaceutical Design The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy
Current Pharmaceutical Design Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets